A bdominal aortic aneurysm (AAA) is a common and highly lethal age-associated vascular degenerative disease. 1 Characteristic pathological features present in both clinical and experimental aneurysms include marked elastin degradation and reduced medial vascular smooth muscle cell (SMC) cellularity in the presence of transmural inflammation and adventitial neovascularity. The exact sequence of and causal relationship between AAA-related pathological events, as well as the time-dependent expression of mural proinflammatory mediators during clinical disease progression, remain poorly understood. 2 Although much emphasis has been placed on the consequences of medial SMC loss and matrix degeneration during aneurysm pathogenesis, the contribution of adventitial neovascularization to human disease progression appears increasingly significant. At the time of surgical repair, aneurysm tissue demonstrates increased mural neovascularization compared to nonaneurysmal aorta, 3 and rupture foci demonstrate increased neovascularity compared to intact aneurysm segments. 4 In experimental aneurysms, proangiogenic mediator expression correlates with transmural inflammation and AAA progression. [5] [6] [7] [8] In an effort to evaluate the utility of mural neovascularity monitoring as a surrogate marker for disease progression we tested the ability of in situ and ex vivo near infrared fluorescent imaging (NIRF) to identify vascular endothelial growth factor receptor (VEGFR) expression in experimental AAAs.
Methods

Model Creation
All protocols were reviewed and approved by the Administrative Panel on Laboratory Animal Care at Stanford University (http:// labanimals.stanford.edu/). C57/Bl 6 ApoE Ϫ/Ϫ mice, 11 to 14 weeks of age, weighing 25 to 30 g were anesthetized with inhaled isoflurane for surgical and imaging procedures and recovered with free access to food and water (Jackson Laboratory, Bar Harbor, Maine). Chronic subcutaneous angiotensin II (Ang II) infusion was used to create suprarenal murine AAAs. 9 After sterile preparation, osmotic minipumps (Alzet Model 2004, Durect Corporation, Cupertino) were inserted underneath the dorsal skin, delivering 1000 ng/kg/min Ang II (Sigma Lot 056K51001) in normal saline. Control mice received mini-pumps loaded with vehicle alone. After their procedures all mice were maintained on high-fat diets (40% kcal lipid, D12109, Resource Diets Inc) for up to 28 days. Using these methods, postoperative mortality was less than 10%.
Aortic Monitoring via Ultra-High Frequency Ultrasound
Transabdominal 40 MHz B-mode ultrasound (US) imaging was used to measure aortic diameter in vivo (supplemental Methods section, available online at http://atvb.ahajournals.org). Imaging was performed at intervals for up to 28 days after mini-pump implantation. Baseline suprarenal aortic diameter ranged from 0.8 to 0.85 mm; diameters Ͼ1.15 mm after Ang II infusion (Ͼ25% increase) were considered aneurysmal. Aortic diameters were measured in the longitudinal scan plane. Validation of US-determined aortic measurements using similar imaging protocols has been previously described. 10, 11 Fluorescence Imaging At 21 to 28 days after mini-pump implantation, Ang II and Control mice underwent fluorescent imaging with scVEGF/Cy (Sibtech Inc), an engineered single chain (sc) VEGF homo-dimer, labeled with Cy5.5-maleimide (GE Healthcare) as previously described. 12 Additional Ang II mice received inactivated scVEGF/Cy (scVEGF/In) to control for nonreceptor-mediated intracellular accumulation (supplemental Methods section). Active or inactive scVEGF/Cy, 7 to 18 g per mouse, was administered via penile vein injection approximately 2 hours before imaging sessions. After anesthetic induction, in vivo fluorescent images were obtained and analyzed via the Maestro NIRF Imaging System (Cambridge Research Instruments Inc). Four mice (2 Ang II scVEGF/Cy, 1 Control scVEGF/Cy, and 1 Ang II scVEGF/In) underwent additional fluorescent imaging with the eXplore Optix NIRF system (GE Healthcare). Postmortem in situ images were obtained after staged abdominal evisceration and subsequent bilateral nephrectomy. After the background signal was removed, scVEGF/Cy signal (signal) from regions of interest (ROI) within aneurysmal as well as grossly uninvolved distal aortic segments were calculated using respective system software. Fluorescent signal intensity reflects the counts per exposure time, normalized to area of ROI. The aortae were explanted and fixed immediately after in situ imaging. After aortic explantation, fixation and sectioning, ex vivo Cy5.5 fluorescence from representative aneurysmal and uninvolved aortic sections was confirmed using a 675/694 nm filtered Meiji MX6300 Fluorescence Microscope.
Angiogenesis Inhibition
After pump implantation, select mice were administered an angiogenesis inhibitor (Exel 0862, Exelixis Inc; 10 mg/kg daily, nϭ6), doxycycline (100 mg/kg, nϭ4), or vehicle alone (nϭ8), all by oral gavage, for 14 days. Mice were then euthanized for histological analysis as described above. Doxycycline is known to limit experimental AAA progression and was used as a positive control. 2 The IC50s (50% inhibitory concentration) of Exel 0862 were: FGFR1ϭ3.7 nmol/L, FGFR2ϭ3.5 nmol/L, Flt-1ϭ13.6 nmol/L, KDRϭ2.4 nmol/L, PDGFRaϭ2.1 nmol/L, and PDGFRbϭ11.1 nmol/L. Exel 0862 has a bioavailability in mice of 52% and a half-life of 2.5 hours.
Tissue Preparation, Histological and Immunohistochemical Staining
Representative aneurysmal and nonaneurysmal aortic segments were selected for pressure perfusion fixation at 100 mm Hg with 4% PFA and embedded in paraffin. Aortic tissues were processed and embedded in paraffin. Blocks were sectioned at 4 m for H&E and elastic Masson (EM) and immunohistochemical (IHC) staining. Sections were incubated for 1 hour at room temperature in primary antibody solutions including: (1) rabbit antimouse smooth muscle ␣-actin (SM-␣) polyclonal antibody to stain for smooth muscle cells (1 g/mL, Laboratory Vision); (2) rabbit antimouse CD31 polyclonal antibody to stain for endothelial cells (1 g/mL, Laboratory Vision); (3) rat antimouse MAC-2 monoclonal antibody to stain for macrophages (0.5 g/mL, Cedarlane); and (4) rabbit antimouse VEGFR-1 and VEGFR-2 polyclonal antibodies (1 g/mL, Laboratory Vision) to stain for VEGF receptors. After staining with the primary antibodies, samples were incubated with the appropriate biotinylated secondary antibodies (Dako Inc & Biocare Medical) for 30 minutes at room temperature. Color development was performed using the DAB color development system (Dako Inc). For CD31/ VEGFR-2, CD31/VEGFR-1, and SM-␣/VEGFR-double staining, the DAB color development system (Dako Inc) was used for BrdU (brown color), and the Fast-red color development system (Biocare Medical) was used for GFAP (red color).
Statistical Analysis
Statistical analyses were performed with StatView (SAS) software. Data were expressed as meanϮSE unless otherwise noted. Individual signal data were compared via 1-way ANOVA using the Fisher PLSD correction for multiple comparisons. The Pearson coefficient was used to calculate the correlation between aortic diameter and signal intensity. Differences were considered significant at PϽ0.05.
Results
VEGFR Signal Intensity Increases With Progressive Aortic Enlargement
Sixteen mice underwent NIRF fluorescence imaging with either scVEGF/Cy (9 Ang II, 5 Control) or scVEGF/In (2 Ang II). Because of intrinsic visceral and renal autofluorescence, AAA-specific signal was not discernable during transabdominal in vivo imaging. Therefore, subsequent signal acquisition and dosimetry calculations were obtained following evisceration and total nephrectomy ( Figure 1 ). Using the Maestro system, signal intensity in aneurysmal aortic segments was significantly higher (0.342Ϯ0.045, meanϮSE) than that obtained from remote nonaneurysmal segments in Ang II mice (0.160Ϯ0.048) and aortae from Control (0.091Ϯ0.043) and Ang II scVEGF/In mice (0.08Ϯ0.02, all PϽ0.05; Figure 2 ). Similar results were obtained using the eXplore Optix system on both whole vessel (supplemental Figure I) as well as tomographic aortic reconstructions (supplemental Figure II) from suprarenal aneurysms as well as noninvolved segments of the more distal aorta. Suprarenal aortic signal intensity correlated closely with US-determined aortic diameter obtained immediately prior to laparotomy ( Figure 3 ).
Colocalization of Cy5.5 Fluorescence With VEGF Receptor Expression
Evidence for Cy5.5 colocalization (representing scVEGF/Cy uptake) within areas of VEGFR-2 expression identified by IHC was confirmed via fluorescence microscopy ( Figure 4A and 4B). More Cy5.5 fluorescence and VEGFR-2 expression were present in aneurysmal as compared to nonaneurysmal aortic segments within the same animal ( Figure 4C and 4D) .
Unexpectedly, maximal Cy5.5 fluorescence was evident in the best preserved, least involved regions of the aortic circumference within aneurysmal sections. No colocalization with VEGFR-2 expression was noted in scVEGF/In mice ( Figure 4E and 4F ).
VEGFR-2, VEGFR-1, and Neovascularization Within Aneurysmal Aortic Segments
Ang II aneurysmal aortic segments demonstrated characteristic regions of medial lamellar disruption ( Figure 5A ) and transmural mononuclear inflammation ( Figure 5B ) in isolated quadrants as previously described. 13 VEGFR-2 expression was evident circumferentially, and was most apparent in the areas of intact media within aneurysmal sections ( Figure 5C ). Costaining with smooth muscle ␣-actin confirmed maximal VEGFR-2 expression within medial smooth muscle cells (Figure 5D ). Nonaneurysmal aortae from control and experimental mice demonstrated intact elastic lamellae, minimal inflammation and reduced VEGFR-2 expression ( Figure 5E and 5F ). Increased transmural VEGFR-1 expression was also present in aneurysmal aortic segments but was limited to the intima in nonaneurysmal aortae (supplemental Figure IIIA and IIIB) .
Transmural neovessel formation was evident within aneurysmal segments as demonstrated by CD-31 immunostaining ( Figure 6A ). By comparison, few neovessels were present in nonaneurysmal aortic segments from either Ang II or Control mice ( Figure 6B ). Costaining studies of VEGFR-2 and CD-31 confirmed increased VEGFR-2 expression in areas of neovessel formation ( Figure 6C ). Within aneurysmal segments there was an abundance of adventitial neovessel formation in intact quadrants ( Figure 6D ) compared to limited constitutive cells and neovascularity present within disrupted regions ( Figure 6E ). CD-31 and VEGFR-1 costaining (supplemental Figure IIIC) also demonstrated the presence of VEGFR-1 expression in areas of adventitial neovascularization (supplemental Figure IIID) . high power field; Doxycycline 10.4Ϯ3.5; and Vehicle 11.0Ϯ3.5; PϽ0.05 AI versus Vehicle, Doxycycline).
Angiogenesis Inhibition Limits AAA Formation
Discussion
In situ NIRF imaging with scVEGF/Cy consistently localized VEGFR expression to regions of concomitant aneurysmal degeneration in experimental AAAs. NIRF signal intensity correlated well with both aneurysm location and diameter. The fidelity of this colocalization was confirmed with ex vivo fluorescence microscopy. Both VEGFR-1 and 2 expression were increased within aneurysmal aortic segments. VEGFR-2 was most intensely expressed in medial smooth muscle cells in intact aortic medial segments adjacent to and across from sites of maximal inflammation and medial lamellar disruption. Similarly, CD31, as a surrogate for neovessel formation, was most abundantly expressed in intact adventitial segments with increased VEGFR-1 and 2 expression in proximity to areas of aneurysmal disruption. The mechanistic significance of neovessel formation in AAA progression was confirmed by profound reductions in mural inflammation and neovascularity after treatment with a broad-spectrum oral angiogenesis inhibitor.
Mural neovascularization is recognized as a salient pathological feature of human AAA disease and may catalyze clinical progression. 3 Conversely, neovascularization may also play a role in protective or compensatory mural remodeling at other stages of human disease. 3, 4, 7, 8, 14, 15 In our experimental construct, functional activity of VEGFR-1 as measured by scVEGF/Cy tracer uptake correlated well with aortic diameter. In addition, treatment with an angiogenesis inhibitor with competitive activity against VEGFR-1 and 2 as well as other vascular growth factor receptors significantly reduced mural inflammation and disease progression. Our data suggests that VEGFR expression and activity is mechanistically relevant to experimental AAA disease, and that VEGFR imaging may provide a useful window on disease progression. 16 -23 If translatable to the human condition, these techniques or suitable alternatives may provide more accurate and timely guidance for suppressive medical therapies than absolute AAA diameter or growth rate alone.
Increased aortic VEGFR expression within aneurysmal segments was confirmed using 2 complementary fluorescence imaging systems as well as fluorescence microscopy and IHC. Although NIRF signal intensity correlated well with increasing aortic diameter, alternative explanations include both increased aortic tissue mass/wall thickness as well as increased neovessel density per unit tissue. To control for intensity per unit area, tomographic in situ NIRF reconstructions were obtained in both axial and coronal planes. This technique confirmed increased signal intensity within aneurysmal planar sections, supporting our initial interpretation (eg, signal production reflected VEGF receptor expression per unit area).
Increased VEGFR-1 and 2 expression was present within aneurysmal aortic segments. VEGFR-1 was expressed in both the intima and adventitia; VEGFR-2 in the media and adventitia. VEGFR-2 colocalized to medial ␣-actin-positive cells. Although ␣-actin may not be expressed exclusively in differentiated vascular smooth muscle cells, 24 the marked regional localization of VEGFR-2 within the media strongly suggested SMC expression. Until recently VEGF and VEGFR were believed to be expressed exclusively by endothelial cells (ECs). Circulating endothelial progenitor cell populations are increased in AAA patients, 25 and VEGF is known to stimulate endothelial progenitor cell mobilization. 26 However, recent in vitro, 27, 28 animal modeling, 29 and human tissue 30 studies demonstrate SMC VEGFR expression and migration in response to VEGF stimulation. Human and mouse embryonic stem cells differentiate into vascular smooth muscle cells that express VEGFR-2. 31 While vascular VEGFR-2 expression is minimal under quiescent conditions, 32 increased expression has been demonstrated in human and animal models of other disease states. 33, 34 The presence of VEGFR-2 within human aortic smooth muscle cells in vitro has also been demonstrated. 35 The finding in the present study of maximal VEGFR-2 expression in aortic medial cells remote from areas of advanced inflammation and lamellar disruption was also unexpected, providing stimulus for further research into mechanisms for aneurysm initiation and localization in this model.
The relative paucity of both VEGFR-2 and CD-31 ϩ cells in disrupted mural quadrants may be a consequence of aortic dissection and contained rupture, both characteristic features of this AAA model. Imaging at earlier intervals may have revealed alternative expression patterns before medial disruption. Indeed, the cellular status of relatively intact quadrants adjacent to areas of medial disruption within aneurysmal segments are probably most representative of the relative neovascularity present in these areas just before medial disruption, and as such are more relevant to mechanisms involved in early disease progression.
Other limitations related to these modeling methods are well known and detailed elsewhere. 36 Confirming the timing, localization, and quantification of VEGFR expression in complementary AAA models may provide additional insights regarding the validity of these observations to human disease. The additional surgical exposure required for either the porcine pancreatic elastase infusion or abluminal calcium chloride application models will likely increase the total area of VEGFR expression present throughout the wound, however reducing the specificity and relevance of receptor localization and quantification for disease monitoring. The limited sensitivity of currently available transabdominal fluorescence imaging systems (in part because of intrinsic autofluorescence) made aortic exposure and evisceration necessary for adequate visualization. Proof of concept has clearly been established by this study, however, and further technical refinements may substantially improve efficacy and provide practical applications to human disease monitoring. Although tomographic imaging demonstrated increased tissue signal production per unit area, in practical terms the specificity of signal intensity as a function of tissue mass versus increased receptor expression is a secondary consideration because of the fact that enlarging aneurysms increase aortic tissue mass as a function of disease progression.
In conclusion, we demonstrate the feasibility of VEGFR expression imaging in experimental AAAs as a surrogate for disease progression. These findings lend further support to prior observations regarding the potential significance of VEGF, VEGF receptor activity, and medial and adventitial neovascularization in AAA pathogenesis. Similar or complementary molecular imaging strategies, if proven relevant to human disease, may expand diagnostic and therapeutic alternatives for AAA disease.
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